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ABSTRACT
Mesenchymal stem cells (MSCs) undergo a decline in function following ex vivo expansion and
exposure to irradiation. This has been associated with accumulation of DNA damage and has
important implications for tissue engineering approaches or in patients receiving radiotherapy.
Therefore, interventions, which limit accumulation of DNA damage in MSC, are of clinical signiﬁ-
cance. We were intrigued by ﬁndings showing that zoledronate (ZOL), an anti-resorptive nitro-
gen containing bisphosphonate, signiﬁcantly extended survival in patients affected by
osteoporosis. The effect was too large to be simply due to the prevention of fractures. More-
over, in combination with statins, it extended the lifespan in a mouse model of Hutchinson Gil-
ford Progeria Syndrome. Therefore, we asked whether ZOL was able to extend the lifespan of
human MSC and whether this was due to reduced accumulation of DNA damage, one of the
important mechanisms of aging. Here, we show that this was the case both following expansion
and irradiation, preserving their ability to proliferate and differentiate in vitro. In addition,
administration of ZOL before irradiation protected the survival of mesenchymal progenitors in
mice. Through mechanistic studies, we were able to show that inhibition of mTOR signaling, a
pathway involved in longevity and cancer, was responsible for these effects. Our data open up
new opportunities to protect MSC from the side effects of radiotherapy in cancer patients and
during ex vivo expansion for regenerative medicine approaches. Given that ZOL is already in
clinical use with a good safety proﬁle, these opportunities can be readily translated for patient
beneﬁt. STEM CELLS 2015; 00:000—000
SIGNIFICANCE STATEMENT
We have shown that zoledronate, a drug already used in patients with osteoporosis and cancer
metastasis to bone, is able to attenuate accumulation of DNA damage in mesenchymal stem
cells following exposure to radiation and following extensive culturing in vitro. By doing so it
maintain their function, i.e. their numbers and ability to differentiate. Given the good safety
profile of zoledronate, new potential applications for the protection of mesenchymal stem cells
from the side effects of radiotherapy in cancer patients and during ex vivo expansion required
for tissue engineering applications may be readily exploited for patient benefit.
INTRODUCTION
Ex vivo expansion or exposure to irradiation
has been shown to be associated with reduced
mesenchymal stem cells (MSC) function and
accumulation of DNA damage [1–5]. For exam-
ple, MSC expanded in vitro or exposed to irra-
diation were reported to have decreased
ability to initiate osteoblastic differentiation [1,
5, 6]. Similarly, mice exposed to irradiation
have been shown to undergo depletion of
mesenchymal progenitors in their bone mar-
row, and increased their differentiation to adi-
pogenesis [2, 6].
These effects can limit clinical efﬁcacy. For
example, bone tissue engineering strategies
are being developed to overcome some of the
limitations of autologous and allogeneic bone
grafts for the repair of large bone defects [7].
This usually involves the use of MSC which
have been expanded in culture combined with
other cell types, growth factors, and carriers
(scaffolds or hydrogels). However, the
decreased ability for osteoblast differentiation
occurring with ex vivo expansion of MSC is
one of the barriers to successful tissue regen-
eration [4, 7, 8]. Ionizing radiation is used to
treat pelvic cancers. Stress fractures or bone
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fragmentation are a signiﬁcant problem arising from this type
of therapy [9, 10]. The risk of hip fracture for a woman under-
going pelvic irradiation for the treatment of cancers such as
cervix, anus, or rectum is three times that of the population
of women who do not receive irradiation and these fractures
are difﬁcult to heal [11]. Total body irradiation (TBI) is used as
conditioning regime in hematopoietic stem cell transplants
and has been shown to increase adipogenesis in the bone
marrow microenvironment [2]. However, increased adipogene-
sis suppresses hematopoiesis, potentially affecting hematopoi-
etic recovery following bone marrow transplant [12]. Thus,
interventions, which attenuate accumulation of DNA damage
in MSC during ex vivo expansion or radiation therapy, are of
clinical importance and an unmet need.
In this study, we identiﬁed zoledronate (ZOL) as a poten-
tial intervention to limit DNA damage accumulation. ZOL is
one of the most potent of the nitrogen-containing bisphosph-
onates (BPs), used clinically for the treatment of osteoporosis,
Paget’s disease and cancer induced bone loss [13]. It acts by
inhibiting the enzyme farnesyl diphosphate synthase (FPPS) in
the mevalonate pathway, thereby preventing the prenylation
of many GTPases, including RAS and RAS homolog enriched in
brain (RHEB) [13, 14]. More recently, bisphosphonates have
been shown to have marked and unexpected effects on sur-
vival. ZOL in combination with statins produced a remarkable
improvement of progeroid features and increased lifespan in
a murine model of Hutchinson-Gilford Progeria Syndrome
(HGPS) [15]. In a double blind placebo-controlled clinical trial
of patients with hip fractures, Lyles et al. found a 28% reduc-
tion in mortality in the patients receiving ZOL compared with
controls [16]. This effect was too large to be simply the result
of prevention of secondary fractures [17].
This prompted us to ask the question whether ZOL was
able to extend survival of MSCs during expansion and irradia-
tion and whether this was related to attenuation of accumula-
tion of DNA damage, one of the important mechanisms of
cellular aging and radiation damage. In an effort to identify
the mechanism of action we reasoned that inhibition of Mam-
malian Target of Rapamycin (mTOR) signaling was a potential
target. It is implicated in lifespan extension in model organ-
isms [18] and requires prenylated proteins such as RAS and
RHEB, whose activity may be modulated by ZOL. In addition,
downstream effectors of mTOR, such as Forkhead Box O3
(FOXO3A), have been recognized as important effectors for
the recruitment of DNA damage response proteins, such as
the protein kinase Ataxia Telangiectasia Mutated (ATM) [19].
Therefore, we asked whether mTOR was involved in the
enhanced DNA repair activity by ZOL. In this study, we pro-
vide evidence that ZOL-treated MSCs extends their lifespan
and retain their function following ex vivo expansion and
exposure to irradiation by inhibition of the mTOR signaling.
MATERIALS AND METHODS
Chemicals
ZOL (kindly provided by FHE), was dissolved in phosphate
buffer saline (PBS) at 1.45mg/ml to obtain a 5-mM concen-
tration and further diluted to the required concentrations in
MSC medium, comprised of Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM; GIBCO, Paisley, U.K.) supplemented with
10% fetal bovine serum (FBS Hyclone, Thermo Scientiﬁc,
Northumberland, U.K.) for in vitro studies. The enantiomeric
pair of pyrindine bisphosphonates, PG-1014491 (1R,6S)-isomer
of cis-2-azabicyclo[4.3.0]nonane-8,8-diphosphonic and PG-
1014493 (1R,6S)-isomer of cis-2-azabicyclo[4.3.0]nonane-8,8-
diphosphonic (kindly provided by Prof. Robert Boeckman, Uni-
versity of Rochester, Rochester, NY) [20] were also dissolved
in PBS and further diluted to obtain the required concentra-
tion of 1mM in MSC medium for in vitro studies. Trans, trans
farnesol (FOH) (Sigma Aldrich, Dorset, U.K.) and geranylgera-
niol (GGOH) (Sigma Aldrich, Dorset, U.K.) were dissolved in
ethanol (EtOH) at 7.33mg/ml and 9.58mg/ml, respectively, to
obtain a 33-mM concentration and further diluted to a ﬁnal
concentration of 33mM in MSC medium for in vitro studies.
The mTOR inhibitors, Rapamycin (Enzo Life Sciences, Exeter,
U.K.) and KU-0063794 (Selleck, Suffolk, U.K.) were dissolved in
dimethyl sulfoxide (DMSO) and used at a ﬁnal concentration
of 10 nM for in vitro while the PI3K/Akt inhibitor, LY294002
(Cell Signalling, Denver, Massachusetts) was dissolved in
DMSO and further diluted to a ﬁnal concentration of 10mM.
Isolation and Culture of MSCs
Human MSCs (hMSC) were derived from bone marrow (BM)
harvested from the pelvis of young patients (2–15 years old)
undergoing osteotomy for reasons other than metabolic disor-
ders at Shefﬁeld Children’s Hospital, U.K. Bone marrow was
obtained following informed written parental consent in
accordance with local research ethical committee approval
and the declaration of Helsinki principles. The bone marrow
was collected in MSC medium containing 0.01% of penicillin/
streptomycin (Sigma, Dorset, U.K.), and 0.1% heparin. Bone
marrow mononuclear cells (MNC) were isolated by density
gradient centrifugation at 800g for 20 minutes using Lympho-
cyte separation medium (1.077g/l, PAA Laboratories, Somer-
set, U.K.). After two washes with PBS (Gibco, Paisley, U.K.),
the cells were plated at 8,000 MNC per square centimeter in
MSC medium and incubated at 378C in 5% carbon dioxide in
air. After 48 hours, the nonadherent cells were removed and
the medium was changed weekly until cells were conﬂuent.
Cells were then harvested using 0.05% Trypsin-1mM EDTA
(Gibco, Paisley, U.K.) and replated at 1,000 per square centi-
meter. Cultures were fed twice weekly and the number of
population doublings (PD) was calculated as log N/Log2,
where N is a ratio of number of cells at conﬂuence and the
number of cells at the start of culture. The assay for the num-
ber of colony forming units ﬁbroblast (CFU-F) generated from
established cultures was obtained by plating hMSC at 10 cells
per square centimeter in duplicate and incubating for 14 days
at 378C in 5% CO2 in air. Cultures were stained using Wright’s
Giemsa and purple stained colonies consisting of a minimum
of 50 cells were counted as individual CFU-ﬁbroblast (CFU-F).
The assay for the number of CFU osteoblasts (CFU-O) was
obtained by plating 20 cells per square centimeter from
established cultures in MSC medium supplemented with
osteogenic supplements composed of 0.05mM L-Ascorbic Acid
(Sigma Aldrich, St. Louis, Missouri), 10mM b glycerophos-
phate (Sigma Aldrich, St. Louis, Missouri), and 100 nM dexa-
methasone (Sigma Aldrich, St. Louis, Missouri). Cells were
maintained for 14 days at 378C in 5% CO2 in air and fed twice
weekly. At day 14, colonies were stained for alkaline phospha-
tase (ALP) enzymatic activity using 86R ALP kit (Sigma Aldrich
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St Louis, Missouri) according to the manual instructions. The
colonies comprising of at least 40 cells with a deﬁnite centre
of origin and stained for ALP were considered as one CFU-O.
CFU adipocyte (CFU-A) were obtained by plating hMSC from
established cultures at limiting dilutions ranging from 105 to
6.253 103 (eight wells per dilution) at ﬁnal volume of 100ml
in a 96-well plate as described previously [4, 21].
Differentiation of hMSC
hMSC seeded at 1.23 103 and 2.83 103 per cm2 were
induced to undergo osteogenic and adipogenic differentiation,
respectively, using osteogenic and adipogenic supplements as
speciﬁed above. Cells were fed twice weekly either with
osteogenic medium or with adipogenic medium and after 2
weeks, total RNA was extracted using RNAqueous 4PCR Kits
(Ambion, Warrington, U.K.) according to manufacturer’s
instructions. Two micrograms of total RNA was used for
reverse transcription using the ﬁrst Strand cDNA Synthesis Kit
(GE Healthcare, Buckinghamshire, U.K.). Quantitative real-time
polymerase chain reactions (RT-PCR) were performed using
SYBR green PCR Master Mix (Eurogentec, Romsey, U.K.) and
0.1 mM primers (Supporting Information Table S1). PCR ampli-
ﬁcation was carried out according to the following conditions:
508C for 2 minutes, 958C for 10 minutes (1 cycle); 958C for 15
seconds, 608C for 1 minute, (40 cycles). The data were ana-
lyzed using SDS 2.0 software.
DNA Damage Assessment by cH2AX Immunostaining
and Comet Assay
DNA damage was induced by exposing hMSC to a 137Cs
Gamma source. DNA double strand breaks were identiﬁed by
cH2AX staining. Brieﬂy, cells were ﬁxed with 4% paraformalde-
hyde, permeabilized with 0.5% Triton-X (Sigma, Dorset, U.K.),
and blocked with 5% normal goat serum (DAKO, Glostrup,
Denmark) in PBS, followed by incubation overnight at 48C
with primary antibody, anti-phospho-histone H2AX (Ser139)
(Millipore, Billerica, Massachusetts) used at 1:800 in 5% nor-
mal goat serum. Cells were then incubated in anti-mouse ﬂu-
orescein isothiocyanate (FITC) conjugated secondary antibody
(Insight Biotechnology, Santa Cruz, Middlesex, UK) at 1:200 in
PBS for 1 hour at room temperature. Slides were mounted
using VectaShield containing 40, 6-diamidino-2-phenylindole
(DAPI) to stain the nuclei blue. Cells were viewed using a
633objective in an Inverted Zeiss LSM 510 NLO microscope.
Nuclei with DNA damage cH2AX foci were scored using
ImageJ 1.45 software (http://rsbweb.nih.gov/ij/). Single-cell
gel electrophoresis alkaline comet assay was also used to
assess cellular DNA damage. Brieﬂy, cells were washed in cold
PBS, suspended at 1:10 ratio in 0.5% low-melting point aga-
rose (378C) on precoated slides, lysed, and subjected horizon-
tal electrophoresis under alkaline conditions. After 30 minutes
of low voltage electrophoresis, slides were stained with ethi-
dium bromide and visualized under a ﬂuorescent microscope.
DNA damage was scored by classiﬁcation of tail content in
ﬁve categories (CC1-CC5) based on increasing tail moment.
Overall score was calculated as percentage of cells in each
comet category for each treatment CC5 signifying maximum
DNA damage.
Cell Cycle Analysis
hMSC cultures treated in presence or absence of ZOL for 3
days were irradiated (3Gy) and ﬁxed for cell cycle analysis 4
hours post irradiation. Brieﬂy 106 cells were ﬁxed in prechilled
100% EtOH added dropwise and incubated on ice for 15
minutes. At the time of analysis, the cells were centrifuged,
washed in PBS and stained with a freshly made solution con-
taining 0.1mg/ml propidium iodide (Sigma, Dorset, UK), 0.1%
Triton x-100 and 0.2mg/ml ribonuclease A (Sigma, Dorset,
UK) in PBS. All samples were incubated for 30 minutes at
room temperature in the dark. Cell cycle distribution was
determined by ﬂow cytometry (LSR II BD Biosciences, Oxford,
UK) for 10000 events at a ﬂow rate not exceeding 500 cells
per second and data were analyzed using FlowJo software.
Western Blotting
Cells were lysed with mammalian cell lysis buffer supple-
mented with 2% protease and 1% phosphatase inhibitor cock-
tails (Sigma, Dorset, U.K.) to obtain total lysates. For nuclear
and cytoplasmic fractions, the homogenate (total lysate) was
centrifuged at 1,500g for 5 minutes to sediment the nuclei.
The supernatant was then resedimented at 15,000g for 5
minutes, and then the resulting supernatant formed the cyto-
plasmic fraction. The nucleic sediment was washed three
times and resuspended in PBS containing 0.5% NP-40 to
extract nuclear proteins. The extracted material was sedimen-
ted at 15,000g for 10 minutes and the resulting supernatant
was termed the nuclear fraction. Forty micrograms of total
cell or fractionated lysate was separated using a 10% tris gly-
cine gel and transferred to Immobilon-P membranes (Milli-
pore Corp., Billerica, MA). Membranes were blocked using 5%
dry milk for all antibodies with the exception of p-FOXO3A,
FOXO3A, p-ATM, and ATM, which were blocked in 5% bovine
serum albumin (BSA; Sigma, Dorset, U.K.). Membranes were
then incubated with primary antibodies anti-mTOR, AKT,
P70S6K, FOXO3A, and their phosphorylated forms p-mTOR, p-
AKT, p-P70S6K, p-FOXO3A, p-ATM (Cell Signaling Technology,
Denver, Massachusetts), Ku70, Ku80 (Thermo Scientiﬁc,
France), and RAD51(Santa Cruz Biotechnology, Heidelberg,
Germany) at 1:1,000. GAPDH (Abcam, Cambridge, U.K.) was
used at 1:30,000, LAMIN B1 (Invitrogen, Paisley, U.K.) and
RAP1A (SantaCruz, Middlesex, U.K.) at 1:3,000 and bACTIN
(Abcam, Cambridge, U.K.) at 1:10,000. Secondary HRP-
conjugated anti-mouse and anti-rabbit IgG were use at
1:30,000 and 1:1,000, respectively (DAKO, Glostrup, Denmark).
Detection was performed using ECL reaction kits according to
manufacturer’s instruction (GE Healthcare, Buckinghamshire,
U.K.) and quantiﬁcation of the signal was performed using
ImageJ 1.45 software (http://rsbweb.nih.gov/ij/).
Knockdown of FOXO3a Using Small Interfering RNA
hMSC were cultured in 24-well plates (53 104 cells per well)
up to 50% conﬂuence and transfected with FOXO3a siRNA
(50GAGCUCUUGGUGGAUCAUCTT30) or nonsilencing siRNA (50-
CGUACGCGGAAUACUUCGA-30) at 100 nM (Cell Signaling, Den-
ver, Massachusetts) using transfection reagent Lipofectamine
2000 (Invitrogen, Paisley, U.K.) according to manufacturer’s
instructions. Cells were either treated with ZOL (1mM) or PBS
6 hours following addition of siRNA and 72 hours later killed
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to conﬁrm knockdown of FOXO3a by either Western blotting
as described above or immunoﬂuorescence.
For analysis by confocal microscopy hMSC were ﬁxed with
4% paraformaldehyde for 10 minutes at room temperature. Cells
were permeabilized in 0.5% TritonX-100, blocked with PBS con-
taining 2% BSA, and incubated with antibody speciﬁc to FOXO3a
(1:300) or ATM-pS1981 (1:200) followed by Cy3 (red) conjugated
anti-rabbit (1:200) and Alexa 488 (green) conjugated anti-mouse
(1:200) secondary antibodies. Slides were mounted using Vecta
Shield containing DAPI to stain the nuclei blue. Cells were
viewed using a 633objective in an Inverted Zeiss LSM 510 NLO
microscope. The images were analyzed using the NIH ImageJ
1.45 software (http://rsbweb.nih.gov/ij/) Colocalization of the
two proteins was shown as the merged images.
In Vivo Studies Using C57Bl/6 Mice
Mice were injected with ZOL (125mg/kg) or PBS and 3 days
later irradiated at 3Gy or 12Gy and assayed for the presence
of DNA damage foci or the number of clonogenic progenitors
24 hours later. To assay the number of murine CFU-F and
CFU-O, freshly isolated murine bone marrow cells were plated
in six-well culture plates at density of 523 103 cells per
square centimeter, in duplicates in 4ml of murine MSC com-
plete medium or osteogenic differentiation medium, respec-
tively. Plates were incubated for 14 days at 378C in 5% carbon
dioxide in air with medium change every 3 days for 2 weeks.
At day 14, the plates were stained as described earlier.
Data Analysis
Statistical analysis was performed on GraphPad Prism 6 (ver-
sion 6.0.4). Data were expressed as mean6 SD and statistical
comparisons were made by either one-way analysis of var-
iance (ANOVA) or two-way ANOVA followed by post hoc anal-
ysis using Bonferroni post hoc test or Sidak post-test for
multiple comparisons. If comparisons were made between
two groups, Student’s t-test was used. A p< 0.05 was consid-
ered statistically signiﬁcant.
RESULTS
ZOL Extends the Life Span of hMSC and Prevents
Accumulation of DNA Damage with Ex Vivo Expansion
To test whether ZOL increased lifespan of human bone
marrow-derived MSCs (hMSC), these were expanded in the
presence or absence of ZOL (1mM) until they stopped prolif-
erating for 3 weeks, after which they were considered senes-
cent. While control cultures stopped proliferating after 27–31
PD, cultures grown in the presence of ZOL proliferated up to
37–42 PD (Fig. 1A, 1B). During expansion, they retained spin-
dle shaped ﬁbroblast morphology for longer times compared
with untreated cultures (Fig. 1C) and showed reduced levels
of senescent markers p16 and p21 at passage 12 (Fig. 1D;
Supporting Information Fig. S1A). More importantly, hMSC
cultures expanded in ZOL showed a higher content of clono-
genic cells (CFU-F, CFU-O and CFU-A) compared with
untreated hMSCs when replated at low density at passage 8
(Fig. 1E, n5 3 p< 0.001) and showed an increased ability to
differentiate towards the osteogenic and adipogenic lineages.
Indeed a signiﬁcant increase in expression levels of osteoblast
markers, core-binding factor subunit alpha-1, ALP, osteopon-
tin, and osteocalcin (Fig. 1F; Supporting Information Fig. S1B–
S1C; n5 3), was seen in cultures expanded in the presence of
ZOL and induced to differentiate to the osteogenic lineage
after having washed off the drug. Similarly, cultures exposed
to adipogenic supplements showed higher number of adipo-
genic vacuoles and a signiﬁcant increase in adipogenic
differentiation markers, peroxisome proliferator-activated
receptor c (PPAR c) and lipoprotein lipase, in ZOL expanded
cultures compared with PBS (Fig. 1G; Supporting Information
Fig. S1D–S1E).
To determine whether this was associated with decreased
accumulation of DNA damage, cH2AX DNA damage foci were
enumerated at passage 3 (8–10 PD) and after 10 passages
(24–29 PD) in hMSC cultured in the presence or absence of
ZOL (Fig. 1H, n5 3). Both PBS- and ZOL-treated cultures
showed low levels of DNA damage foci at early passage,
whereas at late passage a signiﬁcant increase in the number
of foci was observed in PBS-treated cultures, but not in ZOL-
treated hMSC. These results suggest that ZOL extends the life-
span of hMSC following in vitro expansion and delays the loss
of clonogenic and differentiation ability observed with cellular
aging [4] and this is associated with reduced accumulation of
DNA damage.
ZOL Enhances DNA Repair in hMSC Following
Irradiation and Rescues Their Function
To determine whether ZOL was able to enhance the repair of
DNA damage, hMSC were exposed to ZOL for 3 days and
then exposed to 1, 3, 5, 7 Gy irradiation and assayed at 0, 4,
Figure 1. Zoledronate (ZOL) extends the life span of human mesenchymal stem cell (hMSC) and prevents accumulation of DNA damage
with ex vivo expansion. (A): A representative example of cumulative population doublings (PD) of hMSC with time in culture grown in
the presence (circle) or absence (square) of ZOL at 1 mM (n5 9). (B): Total number of PD; (C) Representative examples of hMSC mor-
phology when cultured in presence or absence of ZOL at passage (p) 4, 8, and 12. (D): A representative example of expression of p16,
p21, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; bottom panel) by Western blot analysis in hMSC cultured in presence or
absence of ZOL at 1 mM at passage 12. (E): Number of colony forming unit-ﬁbroblast (CFU-F), CFU-osteoblast (CFU-O), and CFU-
adipocytes (CFU-A) in hMSC cultures at passage 8 in the presence or absence of ZOL (n5 6). (F): hMSC exposed to osteogenic differen-
tiation supplements for 14 days and assessed for expression of osteogenic differentiation markers core-binding factor subunit alpha,
alkaline phosphatase, osteopontin, and osteocalcin. (G) hMSC exposed to adipogenic differentiation supplements for 14 days and
assessed for expression of adipogenic differentiation markers peroxisome proliferator-activated receptor c, lipoprotein lipase. All markers
were normalized to ribosomal protein L32 (n5 3). (H): A representative example of cH2AX foci (green) and 40, 6-diamidino-2-
phenylindole-stained nuclei (blue) in phosphate buffer saline and ZOL-treated hMSC at passage 3 and 10 (left panel) 633; Number of
DNA damage foci enumerated at passage 3 and 10 in hMSC cultured in the presence or absence of ZOL (n5 3) (right panel). All data
are presented as mean6 SD and analyzed by t-tests or for multiple comparisons by one way analysis of variance with Bonferroni multi-
ple comparison post hoc test *, p< 0.05; **, p< 0.01; ***, p< 0.001; ****, p< 0.0001. Abbreviations: CFU, colony forming unit; LPL,
lipoprotein lipase; OC, osteocalcin; OPN, osteopontin; PBS, phosphate buffer saline; PD, population doublings; PPAR c, peroxisome
proliferator-activated receptor c; ZOL, zoledronate.
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Figure 2. Zoledronate (ZOL) enhances DNA repair in human mesenchymal stem cell (hMSC) following irradiation and rescues their
function. (A): Number of cH2AX foci enumerated in hMSC following irradiation (3Gy) in the presence or absence of ZOL (1mM) and
assessed at 0, 4, 12, 24, and 48 hours post irradiation (scored 25 cells from hMSC cultures from three independent donors). (B): Per-
centage of cells in different comet categories (CC) calculated based on increasing tail moments (CC1-CC5) to determine cellular DNA
damage (n5 3) 203. (C): Number of colony forming unit ﬁbroblast (CFU-F) obtained from hMSC cultures exposed to irradiation (3 Gy)
in the presence or absence of ZOL (n5 3). (D): Representative example of hMSC growth curve showing number of cumulative popula-
tion doublings. Cultures were either left nonirradiated or irradiated at 3 Gy and grown in the presence or absence of ZOL for 3 days,
and 12 hours later cultures were washed free from ZOL and expanded in hMSC medium (n5 3). (E, F): hMSC treated as described in
(D): and at passage 9 exposed to osteogenic and adipogenic differentiation supplements, respectively. Cultures were assessed for the
expression of osteogenic differentiation markers core-binding factor subunit alpha, osteopontin, alkaline phosphatase, osteocalcin, and
adipogenic differentiation markers lipoprotein lipase and peroxisome proliferator-activated receptor c. All markers were normalized to
ribosomal protein L-32 (n5 3). Data expressed as mean6 SD and analyzed by one way analysis of variance (ANOVA) and Bonferroni
post hoc test for multiple comparisons, with the exception of data in panel A which was analyzed by two way ANOVA and Sidak’s post-
test for multiple comparisons *, p< 0.05; **, p< 0.01; ***, p< 0.001; ****, p< 0.0001. Abbreviations: ALP, alkaline phosphatase; CBFA,
core-binding factor subunit alpha; CFU, colony forming unit; IR, irradiation; LPL, lipoprotein lipase; OC, osteocalcin; OPN, osteopontin;
PBS, phosphate buffer saline; PD, population doubling; PPAR c, peroxisome proliferator-activated receptor c; UI, not irradiated; ZOL,
zoledronate.
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12, 24, 48 hours post-irradiation for the presence of DNA
damage foci. A signiﬁcant increase in DNA damage foci was
seen in all cultures immediately after irradiation at all doses
of radiation with the exception of cells exposed to 7 Gy,
which were not viable. No signiﬁcant difference in the num-
ber of foci was observed between irradiated cultures exposed
to ZOL compared with controls at this time point (Fig. 2A;
Supporting Information Fig. S2A, S2B, n5 3). Starting at 4
hours post irradiation, a signiﬁcant decrease in cH2AX foci
was observed in cultures treated with ZOL compared with
control cultures and the difference was more pronounced at
the later time points and at the lower doses of irradiation
(Fig. 2A; Supporting Information Fig. S2A, S2B). Similarly, ZOL-
treated cultures showed a signiﬁcant percentage of cells in
CC1 comet category with no comet tail moment compared
with untreated hMSC that had very few cells in the same
category. Moreover, cells with Comet tail moment in CC3–CC5
were signiﬁcantly reduced in ZOL treatment compared with
untreated hMSC after irradiation (IR) (Fig. 2B). This was
accompanied by protection of the clonogenic ability of hMSC
at 1 and 3 Gy (Fig. 2C; Supporting Information Fig. S2C,
n5 3) and partial protection at 5 Gy (Supporting Information
Fig. S2C, n5 3). Moreover, the lifespan of cells exposed to 3
Gy of irradiation in the presence of ZOL was consistently lon-
ger not only to those exposed to irradiation in absence of
ZOL but also to those not exposed to irradiation. This is
despite ZOL was removed immediately after IR and cells were
expanded in MSC medium (Fig. 2D, n5 3). The same cultures
showed enhanced differentiation ability to osteogenic and adi-
pogenic lineages, which was otherwise impaired following
irradiation, as demonstrated by little or no increase in their
expression of differentiation markers (Fig. 2E, 2F, n5 3).
Together these data suggest that ZOL enhances DNA repair in
hMSC after irradiation and protects their ability to proliferate
and differentiate.
ZOL Repairs DNA Damage by Inhibiting the
Mevalonate Pathway
To determine whether ZOL enhanced DNA repair through the
inhibition of the mevalonate pathway (Fig. 3A), hMSC were
treated with ZOL at increasing concentrations (100 nM–1mM)
for 3 days and expression of unprenylated Rap1A was
assessed. A dose-dependent increase in unprenylated RAP1A
was observed (Fig. 3B; Supporting Information Fig. S3A) and
this was mirrored by a dose-dependent decrease in the num-
ber of cH2AX foci 4 hours after 1 Gy of irradiation (Fig. 3C;
n5 3). More importantly, when the down-stream metabolites,
FOH and GGOH, were added to overcome the inhibition of
FPPS, the DNA repair activity was abrogated (Fig. 3D, n5 3).
Moreover, when we used two BP enantiomers with similar
structure but different inhibitory activity on the FPPS enzyme,
only the enantiomer with the higher potency, 1R,6S-pyrindine
bisphosphonate, PG-1014491 (IC50: 15 nM) was able to
enhance DNA repair (Fig. 3E, n5 3), while the less potent
enantiomer, 1S,6R-pyrindine bisphosphonate, PG-1014493
(IC50: 359nM) [20] did not (Fig. 3F). These data suggest that
Figure 3. Zoledronate (ZOL) enhances DNA repair by inhibition
of the mevalonate pathway. (A): A schematic representation of
the mevalonate pathway. (B): A representative example of expres-
sion of unprenylated Rap1A (top panel) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; bottom panel) in human mes-
enchymal stem cell (hMSC) following treatment with increasing
concentrations of ZOL. (C): Number of cH2AX foci in response to
different doses of ZOL following irradiation at 1Gy. (D): Number
of cH2AX foci in hMSC not irradiated or exposed to 1 Gy of irradi-
ation in the presence or absence of ZOL (1mM) and with the
addition of farnesol (FOH; 33 mM) or geranylgeraniol (GGOH;
33 mM) (n5 3). Ethanol was added as control with ZOL in the
same amount used to dissolve GGOH and FOH. (E): Number of
cH2AX foci in hMSC exposed to irradiation (1 Gy) in the presence
of the octahydropyrindine-BP enantiomeric pair (F) 1R,6S (PG-
1014491) is the stronger inhibitor of farnesyl diphosphate syn-
thase with an IC-505 15 nM, whereas the 1S,6R enantiomer (PG-
1014493) is a weaker inhibitor with an IC-505 359 nM) (n5 3).
Data are expressed as mean6 SD and were analyzed by one way
analysis of variance and Bonferroni post hoc test for multiple
comparisons *, p< 0.05; **, p< 0.01; ***, p< 0.001; ****,
p< 0.0001. Abbreviations: FOH, farnesol; FPPS, farnesyl diphos-
phate synthase; GGOH, geranylgeraniol; GGPP, gernyl-geranyl
phospahate; IR, irradiation; PBS, phosphate buffer saline; ZOL,
zoledronate.
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the DNA repair response induced by ZOL depends on the inhi-
bition of FPPS and the mevalonate pathway.
ZOL Mediates Its DNA Damage Response via the
mTOR Signaling Pathway
To determine whether the action of ZOL might be mediated
by inhibition of mTOR signaling (Fig. 4A) downstream of the
mevalonate pathway, hMSC (n5 3) were cultured in the pres-
ence or absence of ZOL for 3 days and analyzed for protein
expression of Ribosomal Protein S6 Kinase (P70S6K), AKT,
mTOR and FOXO3A and their phosphorylated forms. As
expected no changes in expression of mTOR, AKT, and P70S6K
(Fig. 4B; Supporting Information Fig. S3C, n5 3) was observed
in hMSC, whereas p-mTOR (Ser2448), p-AKT (Ser473), and
p-P70S6K (Thr421/Ser424) and p-FOXO3A (Ser318/321) were
signiﬁcantly reduced on treatment with ZOL (Fig. 4B; Support-
ing Information Fig. S3B). Moreover, when the effects of inhi-
bition of the FPPS enzyme was reversed by adding back the
downstream metabolites, FOH and GGOH, no signiﬁcant
reduction in the expression of these phosphorylated proteins
was observed (Fig. 4B; Supporting Information Fig. S3B),
suggesting that ZOL abrogated both TORC1 and TORC2 medi-
ated mTOR signaling and this was via inhibition of the meval-
onate pathway.
To determine whether inhibition of mTORC2 signaling
resulted in an enhanced DNA damage response, we deter-
mined expression levels of FOXO3A, p-ATM (Ser1981) in
hMSC, which were not irradiated or 10 minutes after IR (1
Gy). Nuclear levels of FOXO3A were signiﬁcantly increased in
ZOL-treated hMSC regardless of irradiation (Fig. 4C; Support-
ing Information Fig. S3D, n5 3). In contrast, p-ATM showed
increased nuclear expression in ZOL-treated cultures only fol-
lowing irradiation (Fig. 4C; Supporting Information Fig. S3E).
On addition of FOH and GGOH, the levels of both FOXO3A
and p-ATM reverted to control levels conﬁrming that inhibi-
tion of mTOR signaling is downstream of the mevalonate
pathway (Fig. 4C; Supporting Information Fig. S3D, S3E). To
determine whether translocation to the nuclei of FOXO3A was
required to enhance DNA damage repair in response to ZOL
treatment, expression of FOXO3A was knocked down and
expression was veriﬁed both by confocal microscopy and by
Western blotting (Fig. 4D, 4E, n5 3). As expected when
FOXO3A was knocked down no expression of FOXO3A was
detected by Western blot and by confocal microscopy. This
also resulted in abrogation of nuclear expression of p-ATM
(Fig. 4D) and no decrease in the number of DNA damage foci
in ZOL-treated cultured 12 hours after irradiation (Fig. 4F,
n5 3). This was in contrast to cultures treated with ZOL and
transfected with a nonsilencing siRNA, where the expected
signiﬁcant decrease in the number of DNA damage foci was
observed (Fig. 4F).
To investigate the type of DNA repair mechanism induced
by ZOL, we quantiﬁed Ku70 and Ku80, which are components
Figure 4. Zoledronate (ZOL) mediates an enhanced DNA damage
response via inhibition of mTOR signaling. (A): A schematic repre-
sentation of the mTOR pathway. (B): A representative example of
expression of p-mTOR, mTOR, p-P70S6K, P70S6K, p-AKT, AKT, and
p-FOXO3A by Western blot in human mesenchymal stem cell
(hMSC) exposed to ZOL alone or in combination with farnesol
(FOH) or geranylgeraniol (GGOH). Phosphate buffer saline was
added in the same amount than ZOL, and ethanol in the same
amount than GGOH and FOH. Protein expression was normalized
to the expression of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). (C): A representative example of expression of nuclear
and cytosolic FOXO3A and p-ATM in nonirradiated hMSC and in
hMSC 10 minutes after irradiation (IR) in the presence or absence
of ZOL normalized to expression levels of LAMINB1 and b-actin,
respectively. (D): A representative example of hMSC transfected
with a nonsilencing RNA (ns siRNA) or a siRNA speciﬁcally
designed to knock down FOXO3a (FOXO3a siRNA) and analyzed
by confocal microscopy for the expression of FOXO3a and phos-
phorylated ATM (p-ATM); 633. (E): A representative example of
Western blot performed for the analysis of the expression of
FOXO3a in hMSC tranfected with ns siRNA or FOXO3a siRNA and
cultured in the presence or absence of ZOL and/or irradiation (1
Gy); (F) Number of cH2AX foci in hMSC transfected with ns siRNA
or FOXO3a siRNA (n5 3). Data are expressed as mean6 SD and
were analyzed by one way analysis of variance and Bonferroni
post hoc test for multiple comparisons *, p< 0.05; **, p< 0.01;
***, p< 0.001; ****, p< 0.0001. Abbreviations: DAPI, 40, 6-
diamidino-2-phenylindole; EtOH, ethanol; GGOH, geranylgeraniol;
IR, irradiation; PBS, phosphate buffer saline; UI, not irradiated;
ZOL, zoledronate.
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of the nonhomologous end joining (NHEJ) mechanism and
RAD51 recombinase protein expression, which is increased in
presence of homologous recombination activity. Expression of
Ku80 was present but remained unchanged following irradia-
tion or ZOL treatment (Supporting Information Fig. S4A, S4B).
In addition, an increase in Ku70 was observed in both
untreated and ZOL-treated cultures following irradiation with
no signiﬁcant differences in expression between the two cul-
tures (Supporting Information Fig. S4A, S4B). In contrast, a
signiﬁcant increase in RAD51 was observed after IR in ZOL-
treated MSC (Supporting Information Fig. S4A, S4B). No signif-
icant difference was found in the number of ZOL-treated MSC
in the S/G2 phase of the cell cycle (Supporting Information
Fig. S4C), suggesting that any change in expression of RAD51
was not due to a change in cell cycle proﬁle. These data sug-
gest that ZOL increases DNA repair by HR.
In addition to determine whether this effect was seen with
other mTOR inhibitors, we exposed hMSC to the inhibitor of
Phosphoinositol-3 kinase Ly294002 and to the inhibitor of mTOR
KU0063794, both resulting in inhibition of both TORC1 and
TORC2. Moreover, we also exposed the cells to rapamycin
known to inhibit mainly TORC1 upon short term exposure [22].
As expected, expression of the downstream targets of TORC1
and TORC2 p-p70S6K, p-AKT, and p-FOXO3a was inhibited by
Ly294002 and KU0063794 (Fig. 5A, n5 3). In contrast, only the
expression of p-p70S6K, but not p-AKT and p-FOXO3a, was
decreased when cells were exposed to Rapamycin (Fig. 5A), in
agreement with the notion that rapamycin inhibits only TORC1.
Similarly, increased nuclear expression of FOXO3a and p-ATM
was seen only in cells exposed to Ly294002 and KU0063794 but
not to rapamycin (Fig. 5B) and this resulted in a signiﬁcant
decrease in the number of cH2AX DNA damage foci (to similar
levels to ZOL) only in cells treated with Ly294002 and
KU0063794 but not with rapamycin (Fig. 5C). Taken together,
these results suggest that abrogation of mTORC2 signaling by
ZOL results in low levels of p-AKT and increased nuclear translo-
cation of FOXO3A, which in turn increases phosphorylation of
ATM in the presence of DNA damage, resulting in an activated
response to DNA damage.
ZOL Protects MSCs from Radiation Induced
Damage In Vivo
To determine whether ZOL was able to protect MSC from
radiation-induced damage in vivo, C57Bl/6 mice (n5 6) were
exposed to ZOL for 3 days before total body irradiation and
culled 24hours after IR. A signiﬁcant increase in the number
of cH2AX DNA damage foci was seen in cortical bone and
bone marrow following IR, which was signiﬁcantly reduced by
pretreatment with ZOL (Fig. 6A, 6B). Irradiation reduced the
number of surviving bone marrow CFU-F and CFU-O, used as
measure of mesenchymal progenitors, but mice exposed to
ZOL had a signiﬁcantly higher number of progenitors com-
pared with untreated controls (Fig. 6C).
Figure 5. Inhibitors of both TORC1 and TORC2, but not rapamy-
cin, promote enhanced DNA repair similar to ZOL in human mes-
enchymal stem cell (hMSC). (A): A representative example of
expression of p-mTOR, mTOR, p-P70S6K, P70S6K, p-AKT, AKT, and
p-FOXO3A by Western blot analysis in hMSC exposed to ZOL at
1 mM, inhibitor of phosphoinositol-3 kinase Ly294002 (10mM),
inhibitor of mTOR KU0063794 (10 nM) and rapamycin (10 nM).
Phosphate buffer saline was added in the same amount as used
for ZOL, and dimethyl sulfoxide was added in the same amount
as used for the other inhibitors as controls. Protein expression
was normalized to the expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). (B): A representative example of expres-
sion of nuclear and cytosolic FOXO3A and p-ATM in hMSC 10
minutes after irradiation (1 Gy) in the presence or absence of
ZOL, Ly294002, KU0063794, and rapamycin normalized to expres-
sion levels of LaminB1 and b-actin, respectively. (C): Number of
cH2AX foci in response to ZOL, Ly294002, KU0063794 and rapa-
mycin following irradiation at 1Gy. Data are expressed as
mean6 SD and were analyzed by one way analysis of variance
and Bonferroni post hoc test for multiple comparisons *,
p< 0.05; **, p< 0.01; ***, p< 0.001; ****, p< 0.0001. Abbrevia-
tions: DMSO, dimethyl sulfoxide; PBS, phosphate buffer saline;
ZOL, zoledronate.
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DISCUSSION
In this study, we were able to demonstrate that ZOL attenuates
accumulation of DNA damage in MSCs during ex vivo expan-
sion or to irradiation and preserves their function. In previous
studies ZOL has been shown to have cytotoxic effects and lead
to loss of stemness when administered to MSC in vitro [23,
24]. However, the concentrations used were 12 to 126 times
higher than in our in vitro studies. Although BPs do not enter
cells readily, we showed that our dose of 1mM was sufﬁcient
to obtain the effects we have described in vitro and the dose
equivalent to that already used in patients affected by cancer-
associated bone loss was appropriate to produce similar results
in vivo [25]. Our studies were performed in MSC derived from
bone marrow of young donors. Further studies will be required
to conﬁrm that similar effects are observed in MSC obtained
from the bone marrow of older donors.
The effects appeared to be mediated via inhibition of the
mevalonate pathway as happens in other BP responsive cells
such as osteoclasts and macrophages [26]. The evidence that
this is the case is strongly supported by the reversal achieved
by adding back appropriate isoprenoid metabolites (e.g., FOH
or GGOH) downstream of FPPS. Furthermore, the differential
effects of the octahydropyrindine enantiomeric pair of N-
containing BPs were related to their known potencies as
inhibitors of FPPS.
We were also able to identify TORC2-FOXO3A-ATM signal-
ing as the molecular mechanism through which ZOL leads to
enhanced DNA repair, downstream of the mevalonate path-
way. Knockdown of FOXO3A, downstream of TORC2, abro-
gated the enhanced DNA damage response promoted by ZOL.
Moreover, the same effect could be obtained using other
mTOR inhibitors capable of inhibiting the TORC2 complex.
Indeed short incubation with the TORC1 inhibitor rapamycin
(3 days), induced little or no signiﬁcant enhancement of DNA
damage repair. This appears in contrast with the results of
Gharibi et al. [27], who showed inhibition by rapamycin of
the PI3K/Akt/mTOR pathway and lower levels of DNA damage
in MSCs. The discrepancy may lie in the time of incubation. In
the study by Gharibi et al. [27], cells were incubated in the
presence of rapamycin for prolonged times (5 weeks), not the
3 days of treatment we used. Indeed, it is known that chronic
administration of rapamycin leads to inhibition of TORC2 as
well as TORC1 [28].
It is unknown whether there is a direct link between the
TORC2-FOXO3A-ATM signaling cascade and the reduced preny-
lation of progerin suggested as mechanism of action in the
study by Varela et al. [15]. The combination of ZOL and statins
has been shown to prolong lifespan in a mouse model of HGPS
and to prevent DNA damage [15]. Accumulation of progerin,
the abnormally splice variants of lamin A, which causes HGPS,
has been shown to accumulate during cellular aging [29] and
to be associated with accumulation of DNA damage [30]. These
evidence suggest that inhibition of prenylation of progerin may
also be a player in the DNA repair activity of ZOL during normal
aging. Therefore, the relationship between the TORC2-FOXO3A-
ATM pathway and reduced prenylation of progerin in promot-
ing the DNA repair activity warrants further investigation.
The involvement of the mTOR–FOXO3A–pATM signaling
suggests that ZOL may attenuate DNA damage accumulation
in other stem cell types as these molecules have been shown
to be central to the survival and function of several stem cell
types. Loss of the DNA damage sensor ATM depleted HSC
[31], exacerbated the loss of melanocyte stem cells in
response to low dose radiation [32], and promoted the loss
of undifferentiated spermatogonia [33]. Depletion of FOXO3A
led to depletion of HSC and neural stem cells [34–36]. Phos-
phorylation of ATM is central to initiate a number of DNA
repair mechanisms including nonhomologous end joining or
homologous recombination (HR) [37]. Our data show that
there is a NHEJ response in MSC regardless of ZOL. This is in
agreement with the work of Oliver et al. [38], which shows
that MSC have a robust NHEJ response to irradiation. In con-
trast, ZOL seems to increase the HR repair activity. Although
more in depth work is required this is an important ﬁnding
which has implication with regard to the level of ﬁdelity
obtained during the repair following ZOL.
This study has potentially important clinical implications in
tissue engineering applications and in the treatment of cancer
patients when radiation therapy is required. ZOL can be used
Figure 6. Zoledronate (ZOL) enhances protection of mesenchy-
mal progenitors from radiation induced damage in vivo. (A):
Representative example of bone marrow (BM) from a mouse 24
hours after exposure to irradiation (3Gy) and stained for cH2AX
foci. Dotted lines indicate endosteal surface. (B): Number of cells
(identiﬁed by 40, 6-diamidino-2-phenylindole staining) with more
than ﬁve cH2AX DNA damage foci (in red) in the bone marrow
(left panel) or adjacent to the cortical bone (right panel). (C): The
number of BM colony forming unit ﬁbroblast (CFU-F) and CFU-
osteoblast (CFU-O) following the same treatment. Data are
expressed as mean6 SD and were analyzed by one way analysis
of variance and Bonferroni post hoc test for multiple comparisons
*, p< 0.05; **, p< 0.01; ***, p< 0.001; ****, p< 0.0001. Abbre-
viations: BM, bone marrow; CFU, colony forming unit; DAPI, 40, 6-
diamidino-2-phenylindole; IR, irradiation; PBS, phosphate buffer
saline; UI, not irradiated; ZOL, zoledronate.
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during ex vivo expansion of MSC before transplantation to delay
cellular aging and preserve their progenitor cell function. In
our previous work, we have shown that treatment of
MSCs with a molecule targeting prion protein prevented accu-
mulation of DNA damage during ex vivo expansion and led to a
10-fold increase in engraftment levels in bone marrow [4].
Whether ZOL will result in a similar outcome will need to be
conﬁrmed.
Radiation therapy is one of the most common treatments
for cancer patients and ZOL has already been used in
cancer patients to reduce bone loss. However, it is usually
administered long after radiation therapy when signs of
severe bone loss appears. Here, we propose that administra-
tion of ZOL should be given before irradiation to prevent the
loss of mesenchymal progenitor and their ability to differenti-
ate to osteoblasts rather than exploit the anti-resorptive prop-
erties when bone loss ensues.
One concern is that ZOL may enhance survival of cancer
associated ﬁbroblast in a similar way to MSCs and this may
promote tumor growth. However, this is unlikely. ZOL has
been given to cancer patients including patients affected by
breast and prostate cancer with no evidence of reduced efﬁ-
cacy of any cancer treatment. This also points to a differential
effect of its action in normal and cancer cells [39] and is in
line with published work showing that reduced mTOR/AKT sig-
naling mediates differential protection of normal cells from
cancer cells [40]. The signaling pathways mTOR has been
shown to be hyper-active in certain cancer types such as
breast, prostate, and hematological malignancies due to loss
of function mutations in tumor suppressor genes such as
PTEN or gain of function mutations in genes such as RAS and
PI3K. This renders cancer cells insensitive to such inhibitory
signals. Considerable effort has been devoted to developing
dual inhibitors of TORC1 and TORC2 in the hope of stopping
the proliferation of cancer cells [41, 42]. Here, we show that
ZOL targets both components of the mTOR signaling pathway
supporting further the view that ZOL may exert a differential
action protecting normal cells and having cytostatic effects on
cancer cells.
CONCLUSION
We have shown that ZOL protects normal MSCs from the
accumulation of DNA damage following expansion and irradia-
tion via mTOR signaling, a pathway which is central to longev-
ity and cancer survival. Our data opens up exciting new
potential applications for the protection of MSCs from the
side effects of radiotherapy in cancer patients and during ex
vivo expansion. Given the good safety proﬁle of ZOL, these
therapeutic opportunities may be readily exploited.
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